Metadon Martindale Pharmaceuticals

Methadone, the active ingredient in Metadon, is an opioid agonist presented as an oral formulation for systemic use. It is employed in the management of opioid dependence and chronic pain, providing substitution therapy and analgesia for adult patients under medical supervision.

GNH USA supplies Metadon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for export to multiple regions. Customers benefit from reliable logistics and responsive technical support.

Methadone is used in opioid‑related pathways to treat dependence and pain.

Opioid dependence: stabilizes patients during withdrawal and supports long‑term maintenance therapy. Chronic pain: provides potent analgesia for severe, refractory pain when other opioids are insufficient. Opioid substitution therapy: replaces illicit opioids with a controlled, oral medication to reduce harm and improve compliance.

Methadone may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects: - Nausea - Constipation - Dizziness - Sweating

Serious or Rare Side Effects: - Respiratory depression - QT interval prolongation - Seizures - Severe allergic reactions (e.g., anaphylaxis)

When prescribing methadone, several safety considerations are essential.

Dose titration: adjust gradually under medical supervision to avoid accumulation. Pregnancy: Category C; weigh potential benefits against risks with a healthcare provider. Breastfeeding: caution advised; monitor infant for sedation or respiratory effects. Concomitant CNS depressants: increased risk of profound sedation and respiratory depression. Risk of dependence: monitor for misuse and diversion. Store at ambient temperature: keep in original container, protect from moisture and heat.

Methadone interacts with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole): may raise methadone plasma levels and cause toxicity. - QT‑prolonging agents (e.g., haloperidol): increase risk of cardiac arrhythmias. - Respiratory depressants (e.g., benzodiazepines): additive suppression of breathing.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may lower methadone concentrations, reducing efficacy. - Antiretroviral drugs (e.g., efavirenz): can alter methadone metabolism, requiring dose adjustments. - Selective serotonin reuptake inhibitors (e.g., sertraline): may enhance central nervous system effects.